These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8931119)

  • 61. Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid
    Matsumoto K; Hasegawa T; Ohara K; Kamei T; Koyanagi J; Akimoto M
    Xenobiotica; 2021 Feb; 51(2):155-166. PubMed ID: 33146575
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients.
    Kendall MJ; Chellingsworth MC; Jubb R; Thawley AR; Undre NA; Kill DC
    Eur J Clin Pharmacol; 1989; 36(3):299-305. PubMed ID: 2744071
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment.
    Boelaert JR; Jonnaert HA; Daneels RF; Schurgers ML; Thawley AR; Undre NA; Cooper DL
    Am J Med; 1987 Oct; 83(4B):107-9. PubMed ID: 3687998
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent.
    Sun WH; Tsuji S; Tsujii M; Gunawan ES; Kawai N; Kimura A; Kakiuchi Y; Yasumaru M; Iijima H; Okuda Y; Sasaki Y; Hori M; Kawano S
    J Pharmacol Exp Ther; 2000 Nov; 295(2):447-52. PubMed ID: 11046075
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
    Turpeinen M; Hofmann U; Klein K; Mürdter T; Schwab M; Zanger UM
    Drug Metab Dispos; 2009 May; 37(5):1017-24. PubMed ID: 19204080
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.
    Hedner T; Samulesson O; Währborg P; Wadenvik H; Ung KA; Ekbom A
    Drugs; 2004; 64(20):2315-43; discussion 2344-5. PubMed ID: 15456329
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aspirin-like drugs, ethanol-induced rat gastric injury and mucosal eicosanoid release.
    Trautmann M; Peskar BM; Peskar BA
    Eur J Pharmacol; 1991 Aug; 201(1):53-8. PubMed ID: 1794414
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A photophysical and photochemical study of 6-methoxy-2-naphthylacetic acid, the major metabolite of the phototoxic nonsteroidal antiinflammatory drug nabumetone.
    Boscá F; Canudas N; Marín ML; Miranda MA
    Photochem Photobiol; 2000 Feb; 71(2):173-7. PubMed ID: 10687391
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography.
    de Jager AD; Hundt HK; Hundt AF; Swart KJ; Knight M; Roberts J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):247-51. PubMed ID: 10821411
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of nabumetone and aspirin on colonic mucosal bleeding time.
    Basson MD; Panzini L; Palmer RH
    Aliment Pharmacol Ther; 2001 Apr; 15(4):539-42. PubMed ID: 11284783
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach.
    Gretzer B; Ehrlich K; Maricic N; Lambrecht N; Respondek M; Peskar BM
    Br J Pharmacol; 1998 Mar; 123(5):927-35. PubMed ID: 9535022
    [TBL] [Abstract][Full Text] [Related]  

  • 72. NSAID inhibition of RGM1 gastric monolayer wound re-epithelialization: comparison of selective Cox-2 versus non-selective Cox inhibitors.
    Giap AQ; Tarnawski A; Hoa NT; Akotia V; Ma TY
    Life Sci; 2002 May; 70(25):3029-37. PubMed ID: 12138016
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Eicosanoid release in the endotoxin-primed isolated perfused rat lung and its pharmacological modification.
    Amann R; Schuligoi R; Peskar BA
    Inflamm Res; 1999 Dec; 48(12):632-6. PubMed ID: 10669114
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of nimesulide, a preferential cyclooxygenase-2 inhibitor, on carrageenan-induced pleurisy and stress-induced gastric lesions in rats.
    Nakatsugi S; Terada N; Yoshimura T; Horie Y; Furukawa M
    Prostaglandins Leukot Essent Fatty Acids; 1996 Dec; 55(6):395-402. PubMed ID: 9014217
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bioequivalence study of nabumetone: tablet versus suspension.
    Daigneault EA; Ferslew KE; Stanton P
    Am J Med; 1987 Oct; 83(4B):11-4. PubMed ID: 3687999
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Investigations of indomethacin-induced gastric ulcer in rats.
    Kapui Z; Boér K; Rózsa I; Blaskó G; Hermecz I
    Arzneimittelforschung; 1993 Jul; 43(7):767-71. PubMed ID: 8369011
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparative irritancy of oxaprozin on the gastrointestinal tract of rats and mice: relationship to drug uptake and effects in vivo on eicosanoid metabolism.
    Rainsford KD
    Aliment Pharmacol Ther; 1988 Oct; 2(5):439-50. PubMed ID: 2979266
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.
    Gretzer B; Maricic N; Respondek M; Schuligoi R; Peskar BM
    Br J Pharmacol; 2001 Apr; 132(7):1565-73. PubMed ID: 11264251
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Influence of the xanthine derivative denbufylline and the anti-inflammatory agent nabumetone on microsomal free radical production and lipid peroxidation in rat liver.
    Barth A; Kaiser N; Löffler U; Sourgens H; Klinger W
    Exp Toxicol Pathol; 1994 Dec; 46(6):483-9. PubMed ID: 7703681
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone.
    Maleev A; Vlahov V; Gruev I; Dierdorf D; Kostova N; Bacracheva N
    Int J Clin Pharmacol Ther Toxicol; 1986 Aug; 24(8):425-9. PubMed ID: 3759278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.